Connect with us


The HKMA Launches Men’s Health Week to Promote and Arouse Public Attention to Men’s Physical and Mental Health


HPV (Human Papilloma Virus) causes more than 70% of anal cancer, oropharyngeal cancer and penile cancer


HONG KONG SAR – Media OutReach – 18 November 2020 – The COVID-19 pandemic has raised health awareness across the globe. But it has been noted that men, compared with women, often are unwilling and do not have the motivation to engage in health-seeking behaviours such as nutritional eating or regular body checks. Cultural and conventional norms on masculinity impact men’s choices in paying attention to their health.  Very often, men seem to demonstrate avoidance and negligence of healthcare which results in delayed diagnosis and treatments. Meanwhile, there is a growing number of men suffering from problems such as prostate and cardiovascular diseases.


To increase men’s awareness to their physical and mental health in Hong Kong, the Hong Kong Medical Association (HKMA) is launching the ‘Men’s Health Week’ from November 16 to 21, in which doctors from different specialties are invited to conduct online seminars and share common health topics with the public such as ‘Diabetes Management/ Hypertension’, ‘Benign Prostatic Hyperplasia’, ‘Cancer Survivorship’, just to name a few.


According to statistics1,2 from the Department of Health and the Hong Kong Cancer Registry of the Hospital Authority (HKCaR), there is an increasing prevalence in the younger population on various men’s health issues. Take prostate cancer, the third leading cause of cancer death in men, as an example. The number of new cases increased by 60% in the past decade, from 1,369 cases in 2008 to 2,204 cases in 2018. Although the median age of incidence is 71, the number of patients aged 50 and above has risen to 10%. Therefore, young people should never take it lightly. And in response to these information, the Hong Kong Medical Association launches “Men’s Health Week” in the hope to promote health awareness among the local male population.


‘Through various talks organized during the Men’s Health Week, we hope to increase the public’s awareness of disease prevention and management, as well as increasing men’s attention to their physical and mental health, thereby improving the overall health of the Hong Kong citizens,’ said Dr. CHOI Kin, President of the HKMA.


HKMA points out that all topics covered during the ‘Men’s Health Week’ are closely related to men’s health in the modern society, which include:


  • Take HPV (Human Papillomavirus) as an example. The virus can be transmitted through sexual contact, some of which are high-risk genotypes that can cause cytopathic changes and cancer. Although men are not at risk of cervical cancer, they are still at risk of being infected by genital warts and other diseases caused by HPV, such as anal cancer (more than 90% is related to HPV), oropharyngeal cancer (70% is linked to HPV) and penile cancer (around 70% is associated with HPV). In the past two decades, there has been a rising trend in these diseases3. In addition, male carriers also have the risk of transmitting the virus to their partners.
  • A survey by the HKMA conducted earlier on ‘Should Boys be offered HPV Vaccination in the Hong Kong Childhood Immunization Programme (HKCIP)’ shows that 72% of the 126 doctors recommended that school boys aged 11-15 to receive HPV vaccination. Those supporters considered that, ‘school boys can also be easily infected with HPV’, ‘HPV vaccine is proven to be highly efficacious’ and ‘the consequences of being infected with HPV is also serious for boys’.
  • According to information from the Census and Statistics Department and the Department of Health, men are more likely to suffer from diseases including chronic respiratory problems, prostate, diabetes, stroke, hypertension and heart diseases due to their poor habits in daily lives. For example, men are relatively more business entertaining but they don’t pay much attention to fitness as women do. In addition, even if there are body signals, men are unwilling to telling others as a matter of reputation, leading to a delay in seeking medical treatment.
  • From the psychological perspective, urbanite is living a hectic pace of life and work, it is therefore inevitable to suffer from mental stress. However, traditional values generally bring greater expectations and pressure to men in various aspects such as family and society. Poor mental health can lead to physical health issues such as depression, stomach ulcers and heart disease. When tackling with stress, men tend to engage in high-risk activities such as drinking and smoking more often in comparison to women. Consequently, they are also more likely to develop cardiovascular and pulmonary diseases.
  • Meanwhile, traditional society expects men to be strong, causing fewer male patients than female in taking the initiative to seek medical treatment. A number of them are reluctant to admit and accept that they have health problems, and many of them have to be accompanied by their family members or are forced to receive treatment. As a result, they are more likely to miss out the ‘golden period’ for treatment. In addition, men are also less likely to relieve stress through sharing with others. In case of depression and other psychological problems occur, cases of suicide and alcohol abuse will be more serious comparing to women.


Dr. MAK Siu King, Vice President of the HKMA, adds that general public are welcomed to participate during the ‘Men’s Health Week’ where medical education seminars will be also held for local and overseas doctors and scholars for in-depth discussion and to enhance the level of the medical profession in Hong Kong.


‘Men’s Health Week’ is organized by the HKMA with an aim to promote men’s health knowledge and arouse attention of the society to men’s health problems, as well as self-care awareness of men in Hong Kong, in turn to enhance the overall men’s health level. At the same time, the government is expected to pay more attention to men’s health and allocate more resources in this aspect, such as expanding the current arrangements of HPV vaccination from schoolgirls to school boys, so that men can maintain a healthy body and mind.


To learn more about the seminars and talks, please log on


For general public who is interested to take part in the event can watch live on [View Image]

Public Talk Information for Men’s Health Week

Date & Time




November 16,


Innovation for Men’s Health: How to Meet the Unmet Need?

Diabetes Management/ Hypertension

Dr. AU YEUNG Yick Cheung

November 17, 5:45-6:45PM

Non-Communicable Disease

Benign Prostatic Hyperplasia / Male Depression

Dr. YEUNG Hip Wo, Victor / Dr. Greg MAK

November 18, 5:45-6:45PM

Communicable Disease

Anal Cancer / Penile Cancer

Dr. WONG Tin Yau, Andrew / Dr. LAM Pei, Wayne

November 19, 5:45-6:45PM


Telemedicine in Stroke Patients / Interventional Treatment for Stroke

Dr. MAK Hoi Kwan, Calvin / Dr. WONG Ping Hong, Derek

November 20, 5:45-6:45PM

Novo Therapies: How to Meet the Unmet Need?

Cancer Survivorship / Support Services Sharing from Cancer Information

Dr. TSANG Wai Kong / Mr. Alan NG, Ms. Natalie FONG


1.     Hospital Authority: Cancer Statistics in 2018


2.     Hospital Authority: Hong Kong Cancer Registry — Top 10 Cancers in Hong Kong

3.     Bailey HH et al.: Journal of Clinical Oncology: American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention, 2016; 34(15): 1803-1812


Pipefy Accelerates Toward the New Year as Momentum Builds


Pipefy, the business process management solution that empowers doers to build their own automated workflows and transform the way they work, today announced triple digit annualized growth in the second half of 2020. In light of accelerated demand for digital transformation due to the impact of COVID-19, the company has also experienced growth in platform usage, renewals and ARR. With version 2.0 of the Pipefy platform expected to move from beta to generally available in early Q1 2021, Pipefy expects to carry this strong momentum into 2021 and beyond.

As global markets continue to shift to a remote work model and the demand to automate and optimize business processes grows, business leaders are searching for new ways to leverage platforms with quick time to value to maximize efficiency, reduce manual tasks and eliminate human error. Pipefy’s strong growth in the second half of 2020 is representative of the platform’s position in the market as an industry-leading, no-code tool for teams and enterprises who want to increase the velocity of their workflow processes — whether in finance and procurement, customer service, marketing, or human resources — while taking advantage of the benefits of workflow automation and end-to-end integration.

“What we are seeing at Pipefy right now is an imminent need for businesses to accelerate their adoption of digital business processes, which tightly aligns with our strengths as a platform,” said Alessio Alion§o, Pipefy Founder and CEO. “Our customers are searching for an intuitive, no-code tool that empowers them to optimize and automate their business processes without writing a single line of code. We are committed to providing our customers a workflow management solution that centralizes their work, integrates with their existing tool stack and allows them the ability to continuously optimize and improve their deliveries.”

Looking to 2021 and Beyond

Pipefy is recognized in Gartners Nov. 2020 Market Guide for Intelligent Business Process Management Suites and named a leader in G2’s Summer 2020 Grid for both Best Workflow Management Software and Best Business Process Management Software. Pipefy has firmly established itself as a global leader in workflow management. Nowhere is this more evident than in the development of Pipefy 2.0, the new-and-improved workflow management platform that will fundamentally change the way organizations work and teams engage with stakeholders like customers, employees and vendors.

Pipefy has found success by being laser-focused on continuous innovation and improvement of our platform, said Alion§o. Pipefy 2.0 speaks to that, with additional functionality added around analytics, enterprise integrations and automation to help our customers not only streamline their current processes, but also continuously find new ways to engage with their employees and vendors, streamline and centralize operations, and expand measurement capabilities and visibility. During a year when people across the globe are trying to do more with less, Pipefy can help.

Pipefy has also made a name for itself by lowering the barrier of entry for users looking to build more efficiency and automation in their workflows. One of the ways Pipefy accomplishes this is by offering a wide selection of plug-and-play workflow templates for some of the most common pain points for both complex and simple processes in finance, human resources, customer service, and more. Templates can be easily customized to fit any operational need, automate manual tasks and integrate with existing ecosystems while dramatically reducing the dependency on and burdening of IT teams, offering not only endless flexibility but an increase in time to value. In the second half of 2020, Pipefy optimized their expansive template library and looks to continue to grow their offerings over the next year.

Pipefy 2H 2020 in Review

  • Named a Top 100 Company to Work For by CEOWorld Magazine
  • Recognized in Gartners Intelligent Business Process Management Suites, Nov. 2020
  • Leader in G2’s Summer 2020 Grid for both Best Workflow Management Software and Best Business Process Management Software
  • Community reached 1K+ active members
  • Close to triple digit annualized growth in ARR and # of licenses
  • Close to 50%+ annualized growth in new deals and logos from partners

About Pipefy

Pipefy is the workflow management software that increases team productivity, centralizes data and standardizes processes for teams like Finance, HR, Customer Service, and more so those requesting services, those processing the requests and those managing the operation are more efficient. Through automated workflows and a no/low-code platform, Pipefy enhances speed, increases visibility, and delivers higher quality outcomes with ready-to-use, customizable workflows. Digitally transform your team in a matter of hours, not weeks or months. The company is headquartered in San Francisco, CA. Try Pipefy today!

Rochelle Clark, Director of Corporate Marketing, [email protected]

Continue Reading


Khoros and Medallia Partner to Provide Brands with the Most Complete View of their Customers and Enhance Customer Experience


Khoros, a global leader in digital-first customer engagement software, today announced it has partnered with Medallia (MDLA), the global leader in experience management.

The partnership will combine the power of Khoros best-in-class solutions for digital customer service (including messaging and chat, online brand communities, and social media management) with Medallias customer feedback management software to capture the voice of customers. Together, the integration will give brands the ability to capture rich customer feedback directly from Khoros offerings providing a more expansive, 360-view of customers, empowering better customer engagement, and delivering the ability to have even more personalized service.

Dan Doman, CTO of Khoros, said, By combining the power of Khoros with Medallia, brands will get an integrated view of their customer conversations as well as the signals they are sending, enabling a truly holistic view of the customers engagement. Were excited to partner with Medallia and, together, help companies strengthen their digital relationships to create customers for life.

To learn more about Khoros and its digital-first customer engagement platform, visit For more information about Medallia, visit

About Khoros Khoros is a global leader in digital-first customer engagement software. We build enterprise software for digital customer service, messaging, chat, online brand communities, and social media management differentiated by award-winning services with 20+ years of experience.

Over 2,000 brands use Khoros to power approximately 500 million daily digital interactions, and create customers for life. Khoros has over 10 industry awards from TrustRadius, Stevie Awards, G2, and more. Khoros, built from Spredfast and Lithium, has 9 offices globally and is part of Vista Equity Partners. For more information, visit

About Medallia Medallia (NYSE: MDLA) is the pioneer and market leader in Experience Management. Medallias award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Medallia captures experience signals created on daily journeys in person, on calls and digital channels, over video and social media and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment.

Media Contacts:

Mandy Mayekawa


[email protected]

Valerie Beaudett


[email protected]

Continue Reading


Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference


Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation„¢ (NPS„¢) technology, today announced that a scientific update on its non-thermal NPS mechanism will be featured at the upcoming Controversies and Conversations in Lasers & Cosmetic Surgery Symposium. Suzanne Kilmer, MD, Clinical Professor at the University of California, Davis, will present an overview of clinical study results demonstrating the safety and effectiveness of the Companys cellular-focused NPS technology in clearing a range of difficult-to-treat skin lesions. The acclaimed Controversies Symposium on December 4th and 5th will be a virtual worldwide assembly of the best and brightest specialists and innovators in the field of energy-based and aesthetic treatments.

We are honored and excited that the ongoing progress of our scientific investigators and advisors showcases the differentiated benefits of Nano-Pulse Stimulation technology and helps clinicians envision the promise of an elegant solution that clears hard-to-treat skin lesions for their patients, said Ed Ebbers, EVP and General Manager, Dermatology, of Pulse Biosciences.

To date, close to 700 patients and more than 3,600 lesions have been successfully treated in clinical studies using NPS technology delivered by the CellFX System. These studies include a spectrum of common skin lesions, notably Sebaceous Hyperplasia, non-genital Warts, Seborrheic Keratoses, Acne, Nevi and nodular Basal Cell Carcinoma.

The company recently announced its quarterly progress on its clinical and regulatory objectives. The clinical evidence supporting the utility of NPS technology delivered by the CellFX System continues to grow as a result of the investigational use by a broad group of aesthetic dermatology key opinion leaders, said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. We continue to advance towards our goal of commercialization of the CellFX System in the aesthetic procedure market and are positioned to potentially receive regulatory clearances in three strategic geographies: the U.S., the European Union and Canada, as early as the end of the first quarter of 2021. We believe this growing library of clinical evidence will play a critical role in the future adoption of our technology.

Virtual Podium Presentation

Nano-Pulse Stimulation Technology by Dr. Suzanne Kilmer, Founder of the Laser & Skin Surgery Center of Northern California Saturday, December 5, 4:13pm-4:23pm Eastern Time

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX System will be the first commercial product to harness the distinctive advantages of the Companys proprietary Nano-Pulse Stimulation„¢ (NPS„¢) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences expectations regarding regulatory clearance and the timing of FDA and other regulatory filings or approvals, including meetings with FDA and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for a specific indication for the treatment of sebaceous hyperplasia (SH) lesions, the ability of the Company to prepare and provide data to FDA and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Companys market opportunity and commercialization plans, including the market for the treatment of SH, future financial performance, the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. Words such as may, will, could, would, should, anticipate, predict, potential, continue, expects, intends, plans, projects, believes, estimates, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.


Pulse Biosciences

Sandra Gardiner, EVP and CFO


[email protected]


Gilmartin Group

Philip Trip Taylor


[email protected]


Tosk Communications

Nadine D. Tosk


[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News39 mins ago

Zuora to Participate in the Barclays Global Technology, Media and Telecommunications Conference

Zuora, Inc. (NYSE: ZUO), the leading cloud-based subscription management platform provider, today announced that its Chief Financial Officer, Todd McElhatton,...

gbafNews28 gbafNews28
News39 mins ago

Maiden Holdings, Ltd. Announces Formation of Genesis Legacy Solutions

Maiden Holdings, Ltd. (NASDAQ: MHLD) (“Maiden”) today announced the formation of Genesis Legacy Solutions (GLS). GLS will specialize in providing...

gbafNews28 gbafNews28
News39 mins ago

Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists

Vapotherm, Inc. (NYSE:VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its...

gbafNews28 gbafNews28
News39 mins ago

Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference

Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation„¢ (NPS„¢) technology, today announced that a scientific update...

gbafNews28 gbafNews28
News39 mins ago

Khoros and Medallia Partner to Provide Brands with the Most Complete View of their Customers and Enhance Customer Experience

Khoros, a global leader in digital-first customer engagement software, today announced it has partnered with Medallia (MDLA), the global leader...

gbafNews28 gbafNews28
News39 mins ago

Pipefy Accelerates Toward the New Year as Momentum Builds

Pipefy, the business process management solution that empowers doers to build their own automated workflows and transform the way they...

gbafNews28 gbafNews28
News39 mins ago

New Rules Lead to a Six-per-cent Reduction in Commuted Values

Released today, the monthly Morneau Shepell Pension Indices condense the journey that pension plans have experienced over the last year...

gbafNews28 gbafNews28
News39 mins ago

IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 3, 2020, the Company granted a newly hired employee equity-based...

gbafNews28 gbafNews28
News39 mins ago

Navitus Health Solutions Receives Two eHealthcare Leadership Awards for Digital Communications

Navitus Health Solutions, a full pass-through pharmacy benefit manager (PBM), announced today that it won platinum awards for Best Annual...

gbafNews28 gbafNews28
News40 mins ago

Citi Appointed by Dimensional Fund Advisors to Provide Securities Services for New Family of Active ETFs

Citi has been appointed by Dimensional Fund Advisors to provide securities services for its new family of actively managed, transparent...